Business Wire

Mundipharma Announces the Licence Extension Submission for Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin) to the European Medicines Agency

22.8.2019 02:01:00 EEST | Business Wire | Press release

Share

STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY

As the European distributor of Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin), Mundipharma welcomes the news that the European Medicines Agency (EMA) has accepted the licence extension submission for these two medicines to treat stage 2 or stage 3 chronic kidney disease (CKD) and albuminuria as an adjunct to standard of care in adults with type 2 diabetes mellitus (T2DM). The submission is based on the results from the landmark Phase III CREDENCE study1 which evaluated the efficacy and safety of canagliflozin versus placebo in this high-risk patient population when used in addition to standard of care.

“Chronic kidney disease is a serious complication of type 2 diabetes, which can increase patients’ risk of developing end-stage renal disease and may reduce their life expectancy by several years.” said Dr Vinicius Gomes de Lima, European Medical Affairs Lead, Mundipharma. “If approved, this licence extension would be a significant step forward to help reduce the associated burden of chronic kidney disease and improve patients’ quality of life.”

Approximately 24 million T2DM patients in Europe are likely to develop diabetic kidney disease (DKD),2 which is projected to rise in line with the increasing prevalence of diabetes. DKD has a major impact on patients’ physical, emotional and financial wellbeing and amplifies the risk of diabetes complications including; cardiovascular disease, a reduced quality of life, infections, fatigue, depression, adverse drug reactions and premature death.3,4

In Europe, Invokana is currently indicated for the treatment of adults with insufficiently controlled T2DM as an adjunct to diet and exercise. The initiation dose is 100mg once daily in adults with an eGFR of ≥ 60 mL/min/1.73 m2 and can be increased to 300mg once daily orally if tighter glycaemic control is needed. Canagliflozin should not be initiated if eGFR is < 60 mL/min/1.73 m2. In patients tolerating canagliflozin whose eGFR falls persistently below 60 mL/min/1.73 m2 the dose should be adjusted to or maintained at 100mg once daily. Canagliflozin should be stopped if eGFR falls persistently below 45 mL/min/1.73 m2.5

The dose of glucose-lowering therapy with Vokanamet should be individualised on the basis of the patient’s current regimen, effectiveness, and tolerability, using the recommended daily dose of 100 mg or 300 mg canagliflozin and not exceeding the maximum recommended daily dose of metformin orally.6

Invokana and Vokanamet have been approved in the European Union since 2013 and 2014 respectively. In July 2018, the treatment labels were updated to include positive cardiovascular and renal outcomes from the CANVAS programme which show a reduction in morbidity and mortality.7

-END-

Notes to the editors:

About the CREDENCE Clinical Trial 1

The CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) study was the first dedicated and full recruited renal outcome trial evaluating renal and cardiovascular outcomes in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) with a sodium glucose co-transporter 2 (SGLT2) inhibitor. It was a Phase III randomised, double-blind, event-driven, placebo-controlled, parallel-group, 2 arm multi-centre study of the effects of canagliflozin on renal and cardiovascular outcomes in subjects with T2DM and CKD. In particular, it compared the efficacy and safety of canagliflozin versus placebo at preventing clinically important kidney and cardiovascular outcomes in patients with T2DM and CKD when used in addition to standard of care, including a maximum tolerated daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB). The study was stopped early in July 2018 due to positive efficacy findings.

About Invokana®5

Invokana (canagliflozin) is an oral, once-daily medication which belongs to a class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors work by inhibiting SGLT2, which promotes the loss of glucose via the urine, lowering blood glucose levels in adults with T2DM. Invokana was approved in the European Union by the European Commission in November 2013. It is indicated for the treatment of adults with insufficiently controlled T2DM as an adjunct to diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance or contraindications and in addition to other medicinal products for the treatment of diabetes. Approval was based on a comprehensive global Phase III clinical trial programme.

About Vokanamet®6

Vokanamet (a fixed-dose combination of canagliflozin and metformin) is approved in the European Union for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. Vokanamet combines two oral glucose-lowering medicinal products with different and complementary mechanisms of action.

About the Mundipharma network

Mundipharma is a global network of privately-owned independent associated companies whose purpose is to move medicine forward. With a high performing and learning organization that strives for innovation and commercial excellence through partnerships, we successfully transformed and diversified our European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as Diabetes, Respiratory, Oncology, Pain and Biosimilars.

References


1 Perkovic, V. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England Journal of Medicine. 2019; 380(24): 2295-2306.
2 Alicic R., et al. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017; 12(12): 2032-2045.
3 CDC. National Chronic Kidney Disease Fact Sheet, 2017. Available at: https://www.cdc.gov/kidneydisease/pdf/kidney_factsheet.pdf. Last accessed July 2019
4 Thomas M., Cooper M., and Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nature Review Nephrology. 2016; (12): 73-81
5 Invokana SmPC. Available at: https://www.ema.europa.eu/en/documents/product-information/invokana-epar-product-information_en.pdf Last accessed July 2019
6 Vokanamet SmPC. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors 20/European_ Commission_final_decision/WC500206514.pdf. Last accessed July 2019
7 Neal B et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine. 2017; 377:644-657

Job code: MBL/DIAB-19020
Date of preparation: August 2019

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Patrice Grand
European Director of Corporate Communications, Mundipharma Ltd
Email: Patrice.Grand@Mundipharma.com

Abbie Bell
Senior Account Manager, Havas SO
E-mail: Abbie.Bell@HavasSO.com
Tel: +44 (0) 20 3196 9919

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phison Launches Purpose-Built Storage Solutions for New Space Economy17.11.2026 16:00:00 EET | Press release

Supercomputing 2026 (SC26) – Phison Electronics (TW:8299TT), a global leader in NAND flash storage solutions, today announced the launch of Pascari Space, a new category of purpose-built SSD solutions engineered for commercial outer space applications and orbital infrastructure, on display this week at the SC26 conference. Built upon Phison's decades of NAND engineering expertise and flight-proven storage heritage, Pascari Space leverages Phison IMAGIN+ customization and design services to deliver mission-specific storage solutions built to withstand the extreme demands of outer space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117623865/en/ Phison Launches Purpose-Built Storage Solutions for New Space Economy As terrestrial data infrastructure faces mounting challenges related to power consumption, cooling demands, physical space constraints and natural disaster risks, enterprise and commercial organizations are incr

IQM unveils Halocene upgrade program at SC26, creating a path to over 1,000 qubits while accelerating integration with AI-based applications17.11.2026 16:00:00 EET | Press release

IQM Quantum Computers (Nasdaq: IQMX), a global leader in integrated quantum computing, today announced an upgrade program for IQM Halocene, its error-correction product line, that gives customers a path from the 150-qubit system of today to the over 1,000-qubit system of the future. Customers can run hybrid workloads today alongside their AI and HPC systems and upgrade to each new Halocene system without downtime as they move toward fault-tolerant quantum computing. IQM’s HPC integration service is included with every upgrade. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117303243/en/ IQM Halocene, the company’s error-correction product line, now offers an upgrade path to over 1,000 qubits on the way to fault-tolerant quantum computing. IQM introduced Halocene in November 2025, starting with a 150-qubit system, and the LUMI AI Factory, coordinated by CSC – IT Center for Science, has since chosen it for LUMI-IQ which wil

Trulioo’s Global Risk Platform Unlocks Device and Behavioral Intelligence Via Bureau Partnership17.11.2026 16:00:00 EET | Press release

Trulioo and Bureau today announced a joint go-to-market partnership that adds Bureau’s device and behavioral intelligence, alongside its proprietary cross-business network graph intelligence for identifying connected fraud activity, to Trulioo’s global risk intelligence platform for fraud and financial crimes. Together, the companies are helping banks, fintechs, payments companies and marketplaces in APAC and the U.S. confirm who someone is and assess whether to trust them, all on one platform. AI is making fraud more complex and harder to detect, and organizations need stronger defenses to keep pace. Identity verification is only part of the picture; businesses also need to understand the risk behind every interaction, from onboarding throughout the customer journey. By partnering with Bureau, Trulioo is adding device and behavioral intelligence to its identity verification and risk signals, creating a tighter mesh of control. As a result, risk and compliance teams can stop more bad a

Xsolla Launches Quest Builder and Backpack, Enabling Video Game Developers to Reward Players With Items to Collect, Own, and Give Away17.11.2026 16:00:00 EET | Press release

Xsolla (USA), Inc., a global commerce company, today announced the launch of Xsolla Quest Builder, a no-code tool that lets video game developers reward players with digital items for reaching goals tracked through game events, alongside Xsolla Backpack, a persistent inventory where players keep those items. Xsolla Quest Builder helps developers acquire new users, improve retention and lifetime value, and learn what players value and want in their games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117128292/en/ Graphic: Xsolla Across the industry, players want more value from games and the digital items they acquire to enhance their in-game experience. To address this, along with rising user acquisition costs facing game developers, Xsolla is introducing a new way for players to complete quests to collect, own, and share digital items from the games they play. Built on Xsolla’s existing commerce infrastructure, Quest B

Phison AI Data Platform Brings Sovereign, On-Premises Generative BI to Enterprises17.11.2026 16:00:00 EET | Press release

Supercomputing 2026 (SC26) – Phison Electronics (TW:8299TT), a global leader in NAND flash storage solutions, today announced the launch of the Phison AI Data Platform (AIDP) with generative business intelligence (GenBI), a turnkey, sovereign AI system that will be showcased at Supercomputing 2026 (SC26) in booth #5413. Powered by Pascari aiDAPTIV ™ Cache Memory technology, Phison AIDP combines locally hosted AI models, integrated inference services, governed analytics and persistent enterprise storage to help organizations unlock business intelligence while maintaining control over their data, infrastructure and AI operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117045294/en/ Phison AI Data Platform Brings Sovereign, On-Premises Generative BI to Enterprises As AI reshapes the competitive landscape, organizations today are facing shrinking time-to-market windows to capture revenue opportunities and service evol

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye